OX Receptor
Signaling Pathway Map
Research Area
- Inhibitory Selectivity
- Solubility
| Catalog No. | Product Name | Solubility(25°C) | ||
|---|---|---|---|---|
| Water | DMSO | Alcohol | ||
| S7585 | SB-334867 | <1 mg/mL | 63 mg/mL | 3 mg/mL |
| S1545 | SB408124 | <1 mg/mL | 36 mg/mL | <1 mg/mL |
| S2160 | Almorexant HCl | <1 mg/mL | 72 mg/mL | 51 mg/mL |
| S3054 | Alverine Citrate | <1 mg/mL | 95 mg/mL | <1 mg/mL |
| S3880 | Schisantherin A | -1 mg/mL | 100 mg/mL | -1 mg/mL |
Isoform-specific Inhibitors
OX Receptor Products
| Catalog No. | Information | Product Use Citations | Product Validations |
|---|---|---|---|
| S7585 |
SB-334867SB-334867 is a selective orexin-1 (OX1) receptor antagonist. |
||
| S1545 |
SB408124SB408124 is a non-peptide antagonist for OX1 receptor with Ki of 57 nM and 27 nM in both whole cell and membrane, respectively, exhibits 50-fold selectivity over OX2 receptor. |
||
| S2160 |
Almorexant HClAlmorexant HCl is an orally active, dual orexin receptor antagonist with IC50 of 6.6 nM and 3.4 nM for OX1 and OX2 receptor, respectively. Phase 3. |
(C) No significant changes were observed compared with PBS control (n = 5) when sSNA is measured as % range. Grouped data for the % range from every treatment group are compared. AXT at 75 mg/kg (n = 4) produced no effect on baseline sympathetic activity. (D) AXT at 30 mg/kg (n = 5) and 75 mg/kg (n = 5) attenuated the effect of intermittent orexin-A (10 pmol×10; n = 5) on sSNA. Statistical significance was determined using one-way analysis of variance followed by Holm-Sidak correction to compare the effects with the control. Data are expressed as mean±S.E.M. ****P<0.0001; ***P<0.001; *P <0.05. #P<0.05 compared with intermittent orexin-A (10 pmol×10).
|
|
| S3054 |
Alverine CitrateAlverine citrate is a drug used for functional gastrointestinal disorders. |
||
| S3880New |
Schisantherin ASchisantherin A, also known as Gomisin C, is a dibenzocyclooctadiene that exhibits anti-tussive, sedative, anti-inflammatory, anti-osteoporotic, neuroprotective, cognition enhancing, and cardioprotective activities. |
| Catalog No. | Information | Product Use Citations | Product Validations |
|---|---|---|---|
| S7585 |
SB-334867SB-334867 is a selective orexin-1 (OX1) receptor antagonist. |
||
| S1545 |
SB408124SB408124 is a non-peptide antagonist for OX1 receptor with Ki of 57 nM and 27 nM in both whole cell and membrane, respectively, exhibits 50-fold selectivity over OX2 receptor. |
||
| S2160 |
Almorexant HClAlmorexant HCl is an orally active, dual orexin receptor antagonist with IC50 of 6.6 nM and 3.4 nM for OX1 and OX2 receptor, respectively. Phase 3. |
2016, 358(3):492-501 |
(C) No significant changes were observed compared with PBS control (n = 5) when sSNA is measured as % range. Grouped data for the % range from every treatment group are compared. AXT at 75 mg/kg (n = 4) produced no effect on baseline sympathetic activity. (D) AXT at 30 mg/kg (n = 5) and 75 mg/kg (n = 5) attenuated the effect of intermittent orexin-A (10 pmol×10; n = 5) on sSNA. Statistical significance was determined using one-way analysis of variance followed by Holm-Sidak correction to compare the effects with the control. Data are expressed as mean±S.E.M. ****P<0.0001; ***P<0.001; *P <0.05. #P<0.05 compared with intermittent orexin-A (10 pmol×10).
|
| Catalog No. | Information | Product Use Citations | Product Validations |
|---|---|---|---|
| S3054 |
Alverine CitrateAlverine citrate is a drug used for functional gastrointestinal disorders. |
||
| S3880New |
Schisantherin ASchisantherin A, also known as Gomisin C, is a dibenzocyclooctadiene that exhibits anti-tussive, sedative, anti-inflammatory, anti-osteoporotic, neuroprotective, cognition enhancing, and cardioprotective activities. |
